Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/216654
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Cuadrado, Antonio | es_ES |
dc.contributor.author | Pajares, Marta | es_ES |
dc.contributor.author | Benito, Cristina | es_ES |
dc.contributor.author | Jiménez-Villegas, José | es_ES |
dc.contributor.author | Escoll, Maribel | es_ES |
dc.contributor.author | Fernández-Ginés, Raquel | es_ES |
dc.contributor.author | García-Yagüe, Ángel Juan | es_ES |
dc.contributor.author | Lastra, Diego | es_ES |
dc.contributor.author | Manda, Gina | es_ES |
dc.contributor.author | Rojo, Ana I. | es_ES |
dc.contributor.author | Dinkova-Kostova, Albena T. | es_ES |
dc.date.accessioned | 2020-07-15T08:28:57Z | - |
dc.date.available | 2020-07-15T08:28:57Z | - |
dc.date.issued | 2020-07-14 | - |
dc.identifier.citation | Trends in Pharmacological Sciences 41(9): 598-610 (2020) | es_ES |
dc.identifier.issn | 0165-6147 | - |
dc.identifier.uri | http://hdl.handle.net/10261/216654 | - |
dc.description.abstract | Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated pro-inflammatory cytokines release (cytokine storm) and loss of T-lymphocytes (leucopenia) characterize the most aggressive presentation. Here we propose that a multi-faceted anti-inflammatory strategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2), can be deployed against the virus. The strategy provides robust cytoprotection by restoring the redox and protein homeostasis, promoting resolution of inflammation, and facilitating repair. NRF2 activators such as sulforaphane and bardoxolone methyl are already in clinical trials. The safety and efficacy information of these modulators in humans, together with their well-documented cytoprotective and anti-inflammatory effects in preclinical models, highlight the potential of this armamentarium for deployment to the battlefield against COVID-19. | es_ES |
dc.description.sponsorship | We are grateful to the Biotechnology and Biological Sciences Research Council (BB/L01923X/1), Tenovus Scotland (T17/14), Cancer Research UK (C20953/A18644), the Autonomous Community of Madrid (grant B2017/BMD-3827), the 'Tatiana de Guzman el Bueno Foundation' (P-024-FTPGB 2018), and the European Regional Development Fund, Competitiveness Operational Program 2014–2020 (P_37_732/2016; REDBRAIN) for funding our research. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.relation | B2017-BMD-3827/NRF24AD-CM | es_ES |
dc.relation.isversionof | Publisher's version | es_ES |
dc.rights | openAccess | es_ES |
dc.subject | Anti-inflammatory | es_ES |
dc.subject | ARDS | es_ES |
dc.subject | Bardoxolone methyl | es_ES |
dc.subject | KEAP1 | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | Sulforaphane | es_ES |
dc.title | Can activation of NRF2 be a strategy against COVID-19? | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.1016/j.tips.2020.07.003 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.tips.2020.07.003 | es_ES |
dc.identifier.e-issn | 1873-3735 | - |
dc.rights.license | https://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.contributor.funder | Biotechnology and Biological Sciences Research Council (UK) | es_ES |
dc.contributor.funder | Tenovus Scotland | es_ES |
dc.contributor.funder | Cancer Research UK | es_ES |
dc.contributor.funder | Comunidad de Madrid | es_ES |
dc.contributor.funder | Fundación Tatiana Pérez de Guzmán el Bueno | es_ES |
dc.contributor.funder | European Commission | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000289 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/100012818 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000268 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100010805 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.pmid | 32711925 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (IIBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
cancov19.pdf | 2,02 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
115
checked on 17-mar-2024
SCOPUSTM
Citations
143
checked on 23-abr-2024
WEB OF SCIENCETM
Citations
133
checked on 25-feb-2024
Page view(s)
193
checked on 24-abr-2024
Download(s)
79
checked on 24-abr-2024